FDA OKs Duaklir Fixed-Dose Combination Inhaler for COPD
The US Food and Drug Administration (FDA) has approved a fixed-dose combination of aclidinium bromide 400 μg and formoterol fumarate 12 μg (Duaklir, Circassia Pharmaceuticals) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The combination is administered twice daily via the breath-actuated inhaler Pressair (AstraZeneca).
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that acts primarily on the M3 receptor to relieve bronchospasm. Formoterol fumarate is a long-acting beta-agonist (LABA) that stimulates B2-receptors, resulting in bronchodilation.
https://www.medscape.com/viewarticle/911168?src=soc_fb_190405_mscpedt_news_mdscp_copd&faf=1
https://www.facebook.com/medscape/posts/10157207204604189
The US Food and Drug Administration (FDA) has approved a fixed-dose combination of aclidinium bromide 400 μg and formoterol fumarate 12 μg (Duaklir, Circassia Pharmaceuticals) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The combination is administered twice daily via the breath-actuated inhaler Pressair (AstraZeneca).
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that acts primarily on the M3 receptor to relieve bronchospasm. Formoterol fumarate is a long-acting beta-agonist (LABA) that stimulates B2-receptors, resulting in bronchodilation.
https://www.medscape.com/viewarticle/911168?src=soc_fb_190405_mscpedt_news_mdscp_copd&faf=1
https://www.facebook.com/medscape/posts/10157207204604189
No comments:
Post a Comment